Cite
HARVARD Citation
Weiss, B. et al. (2021). NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of clinical oncology. 39 (7), pp. 797-806. [Online].